Stryker Co. (NYSE:SYK) Shares Acquired by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. increased its position in Stryker Co. (NYSE:SYK) by 24.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,842 shares of the medical technology company’s stock after buying an additional 2,109 shares during the period. Stryker comprises 0.7% of Thurston Springer Miller Herd & Titak Inc.’s portfolio, making the stock its 29th largest holding. Thurston Springer Miller Herd & Titak Inc.’s holdings in Stryker were worth $4,037,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker in the fourth quarter valued at approximately $25,000. Capital A Wealth Management LLC purchased a new stake in Stryker in the fourth quarter valued at approximately $26,000. Rakuten Securities Inc. grew its holdings in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC purchased a new stake in Stryker in the fourth quarter valued at approximately $30,000. Finally, BankPlus Trust Department purchased a new stake in Stryker in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of SYK stock opened at $382.87 on Thursday. The company has a market capitalization of $146.14 billion, a PE ratio of 49.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The firm has a fifty day simple moving average of $369.68 and a 200-day simple moving average of $376.11. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.50 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio (DPR) is 45.41%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SYK. Barclays boosted their target price on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. BTIG Research set a $403.00 target price on shares of Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Citigroup restated a “buy” rating and issued a $455.00 target price (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Finally, Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a research note on Monday, May 5th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.